Silexion Therapeutics公司宣布，已与一家领先的全球合同开发与生产组织（CDMO）合作，启动了其候选药物Sil204的GMP临床供应生产。与此同时，公司还获得了来自以色列特拉维夫Sourasky医疗中心对其Sil204药物进行2/3期临床试验的新批准。这两项进展标志着该药物临床开发路径上的重要里程碑，为其后续的临床研究推进提供了关键的物料支持和试验场地保障。
Silexion Therapeutics公司宣布，已与一家领先的全球合同开发与生产组织（CDMO）合作，启动了其候选药物Sil204的GMP临床供应生产。与此同时，公司还获得了来自以色列特拉维夫Sourasky医疗中心对其Sil204药物进行2/3期临床试验的新批准。这两项进展标志着该药物临床开发路径上的重要里程碑，为其后续的临床研究推进提供了关键的物料支持和试验场地保障。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.